366 related articles for article (PubMed ID: 7845675)
1. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC.
Eng C; Smith DP; Mulligan LM; Healey CS; Zvelebil MJ; Stonehouse TJ; Ponder MA; Jackson CE; Waterfield MD; Ponder BA
Oncogene; 1995 Feb; 10(3):509-13. PubMed ID: 7845675
[TBL] [Abstract][Full Text] [Related]
2. Mutational analysis of the RET proto-oncogene in 71 Japanese patients with medullary thyroid carcinoma.
Shirahama S; Ogura K; Takami H; Ito K; Tohsen T; Miyauchi A; Nakamura Y
J Hum Genet; 1998; 43(2):101-6. PubMed ID: 9621513
[TBL] [Abstract][Full Text] [Related]
3. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
4. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
Marsh DJ; Mulligan LM; Eng C
Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949
[TBL] [Abstract][Full Text] [Related]
5. Germline RET mutations in MEN 2A and FMTC and their detection by simple DNA diagnostic tests.
Xue F; Yu H; Maurer LH; Memoli VA; Nutile-McMenemy N; Schuster MK; Bowden DW; Mao J; Noll WW
Hum Mol Genet; 1994 Apr; 3(4):635-8. PubMed ID: 7915165
[TBL] [Abstract][Full Text] [Related]
6. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma.
Hofstra RM; Landsvater RM; Ceccherini I; Stulp RP; Stelwagen T; Luo Y; Pasini B; Höppener JW; van Amstel HK; Romeo G
Nature; 1994 Jan; 367(6461):375-6. PubMed ID: 7906866
[TBL] [Abstract][Full Text] [Related]
7. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.
Eng C; Smith DP; Mulligan LM; Nagai MA; Healey CS; Ponder MA; Gardner E; Scheumann GF; Jackson CE; Tunnacliffe A
Hum Mol Genet; 1994 Feb; 3(2):237-41. PubMed ID: 7911697
[TBL] [Abstract][Full Text] [Related]
8. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
[TBL] [Abstract][Full Text] [Related]
9. Novel point mutation in exon 10 of the RET proto-oncogene in a family with medullary thyroid carcinoma.
Oriola J; Páramo C; Halperin I; García-Mayor RV; Rivera-Fillat F
Am J Med Genet; 1998 Jul; 78(3):271-3. PubMed ID: 9677065
[TBL] [Abstract][Full Text] [Related]
10. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC.
Mulligan LM; Eng C; Healey CS; Clayton D; Kwok JB; Gardner E; Ponder MA; Frilling A; Jackson CE; Lehnert H
Nat Genet; 1994 Jan; 6(1):70-4. PubMed ID: 7907913
[TBL] [Abstract][Full Text] [Related]
11. Molecular analysis of the RET proto-oncogene in patients with sporadic medullary thyroid carcinoma: a novel point mutation in the extracellular cysteine-rich domain.
Bugalho MJ; Frade JP; Santos JR; Limbert E; Sobrinho L
Eur J Endocrinol; 1997 Apr; 136(4):423-6. PubMed ID: 9150704
[TBL] [Abstract][Full Text] [Related]
12. Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A.
Landsvater RM; Jansen RP; Hofstra RM; Buys CH; Lips CJ; Ploos van Amstel HK
Hum Genet; 1996 Jan; 97(1):11-4. PubMed ID: 8557249
[TBL] [Abstract][Full Text] [Related]
13. A novel point mutation in the intracellular domain of the ret protooncogene in a family with medullary thyroid carcinoma.
Hofstra RM; Fattoruso O; Quadro L; Wu Y; Libroia A; Verga U; Colantuoni V; Buys CH
J Clin Endocrinol Metab; 1997 Dec; 82(12):4176-8. PubMed ID: 9398735
[TBL] [Abstract][Full Text] [Related]
14. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.
Donis-Keller H; Dou S; Chi D; Carlson KM; Toshima K; Lairmore TC; Howe JR; Moley JF; Goodfellow P; Wells SA
Hum Mol Genet; 1993 Jul; 2(7):851-6. PubMed ID: 8103403
[TBL] [Abstract][Full Text] [Related]
15. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)".
Fink M; Weinhüsel A; Niederle B; Haas OA
Int J Cancer; 1996 Aug; 69(4):312-6. PubMed ID: 8797874
[TBL] [Abstract][Full Text] [Related]
16. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A.
Berndt I; Reuter M; Saller B; Frank-Raue K; Groth P; Grussendorf M; Raue F; Ritter MM; Höppner W
J Clin Endocrinol Metab; 1998 Mar; 83(3):770-4. PubMed ID: 9506724
[TBL] [Abstract][Full Text] [Related]
17. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s.
Zedenius J; Wallin G; Hamberger B; Nordenskjöld M; Weber G; Larsson C
Hum Mol Genet; 1994 Aug; 3(8):1259-62. PubMed ID: 7987299
[TBL] [Abstract][Full Text] [Related]
18. A novel somatic mutation in the RET proto-oncogene in familial medullary thyroid carcinoma with a germline codon 768 mutation.
Miyauchi A; Egawa S; Futami H; Kuma K; Obara T; Yamaguchi K
Jpn J Cancer Res; 1997 Jun; 88(6):527-31. PubMed ID: 9263528
[TBL] [Abstract][Full Text] [Related]
19. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].
Sansó G; Domené HM; Iorcansky S; Barontini M
Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252
[TBL] [Abstract][Full Text] [Related]
20. Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family.
Moers AM; Landsvater RM; Schaap C; Jansen-Schillhorn van Veen JM; de Valk IA; Blijham GH; Höppener JW; Vroom TM; van Amstel HK; Lips CJ
Am J Med; 1996 Dec; 101(6):635-41. PubMed ID: 9003111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
